BHC(SH:600721) Zheng Quan Zhi Xing·2025-05-12 10:39Core Viewpoint - The company held an earnings briefing on May 12, 2025, to discuss its performance and future strategies, emphasizing its focus on technological innovation and market expansion in the pharmaceutical sector [1][2]. Group 1: Financial Performance - In 2024, the company achieved a net profit of 41.48 million yuan, a year-on-year increase of 219.75%, and a non-recurring net profit of 29.65 million yuan, up 176.38% [4]. - The company's revenue for the main business in 2024 was 383 million yuan, with the pharmaceutical research segment contributing 53%, clinical trial segment 39%, and other income 8% [6]. - The first quarter of 2025 showed a main revenue of 96.92 million yuan, a year-on-year increase of 6.65%, with a net profit of 20.72 million yuan, up 0.28% [8]. Group 2: Research and Development - The company plans to increase its investment in AI technology for drug development, collaborating with specialized firms to enhance its capabilities [3]. - In 2024, the total R&D investment reached 46.54 million yuan, accounting for 12.07% of revenue, with a 10.42% increase compared to 2023 [3]. - The company submitted 141 projects for approval in 2024, a 50% increase year-on-year, and received approval for 92 product specifications, a 70% increase [4]. Group 3: Industry Outlook - The CRO industry is currently in a strategic opportunity period, driven by policy innovations, technological advancements, and a reshaping of the global industrial landscape [6]. - The company aims to leverage its core technological capabilities and platform advantages to capture structural growth opportunities in the industry [6]. - The focus for 2025 will be on optimizing operations and expanding the industry chain, with an emphasis on mergers and acquisitions that create technological synergies [8].